Crossref
Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?
Advances in Cell and Gene Therapy · 2018
DOI: 10.1002/acg2.21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Cell and Gene Therapy, 2018. Verfasst von Prajwal Boddu und 1 weiteren Autor:innen. Die Arbeit nennt 67 Literaturangaben. Gefördert von: University of Texas MD Anderson Cancer Center, Leukemia Spore Grant.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Förderung
- University of Texas MD Anderson Cancer Center
- Leukemia Spore Grant
Zitieren
APA
Boddu, P., & Ravandi, F. (2018). Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?. Advances in Cell and Gene Therapy. https://doi.org/10.1002/acg2.21
Vancouver
Boddu P, Ravandi F. Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?. Advances in Cell and Gene Therapy. 2018. doi:10.1002/acg2.21
BibTeX
@article{Boddu2018,
author = {Boddu, Prajwal and Ravandi, Farhad},
title = {Return of gemtuzumab ozogamicin in acute myeloid leukemia-Is it for everyone with CD33 + disease?},
journal = {Advances in Cell and Gene Therapy},
year = {2018},
doi = {10.1002/acg2.21}
}
EUVIMED